Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A

 Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A

Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A

Shots:

  • Pfizer and Sangamo report follow-up data from the P-I/II Alta study assessing giroctocogene fitelparvovec (SB-525, or PF-07055480) in 11 patients aged 18-47yrs. with severe hemophilia A
  • 5 patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay as long as 61 wks. post-treatment. No patients experienced bleeding events or required FVIII infusions
  • The P-III study of the therapy is ongoing, for which the company is anticipating the first dosing of a patient in H2’20. The therapy has received the US FDA’s ODD, RMAT and EMA’s ODD

Click here to read full press release/ article | Ref: Buinesswire | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post